Brain Cancer Clinical Trial
Official title:
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
Status | Terminated |
Enrollment | 28 |
Est. completion date | April 2015 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Newly diagnosed high grade glioma (WHO Grade III and IV) - Brain magnetic resonance imaging (MRI) scan with gadolinium contrast - Patient must have normal organ and marrow function as defined below: - Absolute neutrophil count >= 1,500/mm^3; - Platelet count >=100,000/mm^3; - Hemoglobin >= 10g/dL; - Blood urea nitrogen and serum creatinine both =< 1.5 times upper limit of normal (ULN); - Total bilirubin both =< 1.5 times ULN; - SGOT and SGPT both =< 3 times ULN; - Alkaline phosphatase =< 2 times ULN. - >=18 years of age; - Karnofsky Performance Score >= 70; - Life expectancy >= 8 weeks; - Negative serum or urine beta-hCG pregnancy test at screening for patients of child bearing potential; - Men and women with reproductive potential must agree to use an acceptable method of birth control (surgical, hormonal or double barrier, ie, condom and diaphragm) during treatment and for 6 months after completion of treatment; - Patient or their legal proxy must provide written informed consent prior to registration on study; - Residual measurable disease. Exclusion Criteria: - Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study; - Prior radiation therapy to the brain; - Prior treatment with Chemotherapy or Targeted agent - Previous (within last 5 years) or current malignancies at other sites except for adequately treated basal cell or squamous cell skin cancer in situ carcinoma of the cervix; - (Uncontrolled High blood pressure >150/100 - Common Terminology Criteria Adverse Event 3.0 >= Grade 2 congestive heart failure (CHF); - History of myocardial infarction within 6 months; - History of stroke within 6 months; - Clinically significant peripheral vascular disease; - Evidence of bleeding diathesis or coagulopathy; - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the first dose of bevacizumab or anticipation of need for major surgical procedure during the course of the study; - Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to study enrollment; - Urine protein/Creatinine ratio >= 2.0 at screening; - Serious, non-healing wound, ulcer, or bone fracture; - Inability to comply with study and/or follow-up procedures; - Glioma showing active intratumoral bleeding; - Patients on enzyme-inducing anti-epileptic drugs; - Known Positive HIV-1, hepatitis B surface antigen, or hepatitis C antibody; - Medications like nonsteroidal antiinflammatory drugs, antipsychotics, iodides, and angiotensin-converting enzyme inhibitor, If they are receiving them, they must have been discontinued for 7 days prior to initiating lithium; - Any previous cytotoxic drug therapies, excluding corticosteroids and temozolomide concurrent with radiation therapy; - Any known genetic cancer-susceptibility syndromes; - Acute infection: any active viral, bacterial, or fungal infection that requires specific therapy. - Active uncontrolled infection - examples include sexually transmitted disease, herpes, scrofula, malaria, etc.; - Fever > 101.5 degrees Fahrenheit; - Unstable or severe intercurrent medical conditions such as unstable angina, uncontrolled arrythmias, Crohn's disease, ulcerative colitis, psoriasis, etc.; - Implantation of Gliadel wafers at surgery; - Patients with organ allografts; and - Allergies to reagents used in this study. |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | New York University Clinical Cancer Center | New York | New York |
United States | Overlook Hospital | Summit | New Jersey |
Lead Sponsor | Collaborator |
---|---|
New York University School of Medicine | Atlantic Health System, Genentech, Inc. |
United States,
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median Progression-Free Survival (PFS) | PFS defined as time from date of diagnosis to most recent follow up, disease progression, or death. Disease progress defined as either clinical deterioration or radiographic progressive disease on magnetic resonance imaging (MRI) per updated response assessment in neuro-oncology criteria (Wen, et al). | Up to 50 months | No |
Secondary | Median Overall Survival (OS) | OS defined as time from diagnosis to most recent follow up or death. | Up to 50 months | No |
Secondary | Number of Patients With Grade 3 or 4 Adverse Events | Adverse events evaluated per CTCAE 3 | The whole time while on treatment and 30 days after the treatment | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
Completed |
NCT04114786 -
3D Printed Mask for GBM and Brain Mets
|
N/A | |
Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT02852655 -
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Completed |
NCT01650922 -
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples
|
N/A | |
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Completed |
NCT00505141 -
Urban Environmental Exposures and Childhood Cancer
|
N/A | |
Completed |
NCT00504660 -
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
|
Phase 2 | |
Completed |
NCT00979810 -
Image-Guided Stereotactic Biopsy of High Grade Gliomas
|
N/A | |
Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
Active, not recruiting |
NCT02851706 -
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
|
||
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Completed |
NCT01012609 -
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
|
Phase 2 | |
Completed |
NCT00782756 -
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
|
Phase 2 | |
Terminated |
NCT03149575 -
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
|
Phase 3 | |
Completed |
NCT01974804 -
Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
|
||
Withdrawn |
NCT01320787 -
18-F-Fluoroacetate as PET Imaging Agent
|
Phase 1 |